Riskpilot← Back to searchSign inGet full accessCymab ApS
APSActiveCVR 39859173Ole Maaløes Vej 3Manufacture of pharmaceutical preparations · NACE 2120Est. 20183 employees
Revenue 2024
DKK -2M
+62% vs 2023
EBITDA margin
281.8%
-73% vs 2023
Equity ratio
-100.3%
Financial strength
Net profit 2024
DKK -4,6M
-79% vs 2023
| Revenue | DKK -2M | +62% |
| EBITDA | DKK -5,5M | -73% |
| Net profit | DKK -4,6M | -79% |
| Total assets | DKK 12,6M | +127% |
| Equity | DKK -12,7M | -58% |
| Employees | 3 | — |
Legal name
Cymab ApS
CVR number
39859173
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
10. september 2018
Share capital
DKK 50.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed indenfor forskning, udvikling og markedsføring af farmaceutiske og medicinske præparater samt anden efter bestyrelsens skøn beslægtet virksomhed.
Address
Ole Maaløes Vej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -2.422 | 0 | -567 | 0 | -1.206 | -1.952 |
| Staff expenses | -0 | -0 | -166 | -742 | -1.969 | -3.549 |
| EBITDA | -2.422 | -1.077 | -733 | -1.909 | -3.175 | -5.500 |
| Depreciation & amort. | -2 | -3 | -3 | -3 | -3 | -1 |
| EBIT | -2.424 | -1.080 | -736 | -1.912 | -3.178 | -5.502 |
| Net financials | -206 | -164 | -179 | -230 | -337 | -604 |
| Profit before tax | -2.630 | -1.244 | -915 | -2.142 | -3.515 | -6.106 |
| Tax | -576 | -289 | 27 | -601 | -934 | -1.478 |
| Net profit | -2.054 | -956 | -943 | -1.541 | -2.581 | -4.628 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 3.492 | 343 | 383 | 5.166 | 5.556 | 12.611 |
| Equity | -2.004 | -2.959 | -3.902 | -5.443 | -8.024 | -12.651 |
| Long-term debt | 0 | 0 | 0 | 4.540 | 12.022 | 23.254 |
| Short-term debt | 5.495 | 3.302 | 4.284 | 6.069 | 1.558 | 2.009 |
| Total debt | 5.495 | 3.302 | 4.284 | 10.609 | 13.579 | 25.263 |
EBITDA margin
-550045700.0%
This company
15.8%
Market median
-3481301999% vs market
20192024
Equity ratio
-100.3%
This company
38.2%
Market median
-363% vs market
20192024
Return on equity
-462762400.0%
This company
18.4%
Market median
-2515013143% vs market
20192024
Net profit margin
-462762400.0%
This company
8.1%
Market median
-5713116149% vs market
20192024
Asset turnover
-0.15×
This company
1.12×
Market median
-113% vs market
20192024
Debt / equity
2.00×
This company
0.62×
Market median
-223% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-09-10 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AR Management | Management | 2024 | — | — |
SL Management | Management | 2023 | — | — |
JH Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
KF Management | Management | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2018 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ebumab Holding ApS | Company | 100.0% | 100.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Wandall Holding ApS
Cymab ApS Board members of Cymab ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anne Reker Cordt | Management | 0 companies |
| Stine Louise Reedtz Kjellev | Management | 0 companies |
| Johan Henrik Faber | Chief Executive Officer | 0 companies |
| Kurt Flemming Holmsted | Management | 0 companies |
| Søren Erik Bjørn | Board of Directors | 0 companies |
| Thomas Dal Stenfeldt Batchelor | Board of Directors | 0 companies |
| Kim Stengaard Holmsted | Chairman | 0 companies |
| Hans Heugh Wandall | Chairman | 0 companies |
| Mads Nikolaj Behrndt-Eriksen | Board of Directors | 0 companies |